New study tests safer version of muscle stiffness drug
NCT ID NCT07097701
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new extended-release form of mexiletine (mexiletine PR) against the standard immediate-release version in people with non-dystrophic myotonias, a group of rare genetic disorders that cause muscle stiffness. About 24 adults aged 16 and older will take each version for 12 weeks to see which is safer and better tolerated. The goal is to find a treatment that controls symptoms with fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universitair Ziekenhuis Leuven"UZ Leuven Gasthuisberg Campus Herestraat 49 Leuven, 3000"
RECRUITINGLeuven, Belgium
Contact
Contact